Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Jul;21(5):307-10.
doi: 10.1007/s12149-007-0020-4. Epub 2007 Jul 25.

Whole-body iodine-131 Metaiodobenzylguanidine Imaging for Detection of Bone Metastases in Patients With Paraganglioma: Comparison With Bone Scintigraphy

Affiliations
Case Reports

Whole-body iodine-131 Metaiodobenzylguanidine Imaging for Detection of Bone Metastases in Patients With Paraganglioma: Comparison With Bone Scintigraphy

Tetsuya Inoue et al. Ann Nucl Med. .

Abstract

Iodine-131 metaiodobenzylguanidine ((131)I-MIBG) therapy is an effective treatment for patients with malignant paraganglioma for which surgical resection is not indicated. We performed high-dose (131)I-MIBG therapy on two patients with malignant paraganglioma and multiple bone metastases. The bone metastases were diagnosed by magnetic resonance imaging (MRI). Metastatic bone lesions were evaluated by whole-body (131)I-MIBG imaging and bone scintigraphy. Whole-body (131)I-MIBG imaging showed extensive metastatic bone lesions, whereas conventional bone scintigraphy did not. There was a remarkable discrepancy between (131)I-MIBG imaging and bone scintigraphy in the diagnosis of metastatic bone lesions of malignant paraganglioma in our two patients. High-dose (131)I-MIBG imaging may detect early stages of bone metastases, compared with bone scintigraphy, in patients with malignant paraganglioma.

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources

Feedback